855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study

作者：C. Toullec, H. Seo, Andrew Robinson, H-H. Chou, P. Salman, François Ghiringhelli, Özgür Özyılkan, C.I. Rojas, Mehmet Alı Nahıt Şendur, C. Le Tourneau, Chung-Yang Yen, S. Aksoy, Sebastian Ochsenreither, E.P. Yanez Ruiz, S.Y. Rha, Ronnie Shapira‐Frommer, Qiaofei Liu, Marguerite du Plessis, T. Keenan, C-H. Hsu · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.917 · 被引用次数：3 · 研究领域：Cancer Immunotherapy and Biomarkers、Radiopharmaceutical Chemistry and Applications、Lung Cancer Treatments and Mutations